Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.52 |
| ▸ | AKT2 | P31751 | 5/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1501534 | 0.89 | AKT1 (0.54) | AKT1AKT2JAK2KCNH2 | |
| SCHEMBL18203546 | 0.88 | JAK2 (0.55) | AKT1AKT2JAK2KCNH2 | |
| SCHEMBL1351051 | 0.88 | AKT1 (0.52) | AKT1AKT2JAK2KCNH2 | |
| Hydrochloric Acid SCHEMBL1351809 | 0.87 | AKT1 (0.51) | AKT1AKT2JAK2KCNH2 | |
| Hydrochloric Acid SCHEMBL3781474 | 0.87 | AKT1 (0.51) | AKT1AKT2JAK2KCNH2 | |
| SCHEMBL12832478 | 0.86 | JAK2 (0.49) | AKT1AKT2JAK2KCNH2 | |
| SCHEMBL1501662 | 0.83 | AKT1 (0.50) | AKT1AKT2JAK2KCNH2 | |
| SCHEMBL2899242 | 0.83 | AKT1 (0.58) | AKT1AKT2JAK2KCNH2 | |
| SCHEMBL1351170 | 0.83 | AKT1 (0.47) | AKT1AKT2JAK2KCNH2 | |
| SCHEMBL3788879 | 0.83 | JAK2 (0.55) | AKT1AKT2JAK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910561-B2 | Cancer; such as 3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridin-5(6H)-one; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080287457-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287457-A1 | Inhibitors of Akt Activity | AKT3, MTOR, STK3 | AKT1 11/4885AKT2 7/4885JAK2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.